Seres Therapeutics Inc MCRB:NASDAQ

Last Price$3.34NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22

Today's Change-0.28(7.73%)
Bid (Size)$3.30 (12)
Ask (Size)$3.34 (1)
Day Low / High$3.22 - 3.61
Volume947.5 K
 

View Biotechnology IndustryPeer Comparison as of 05/18/2022

 

Seres Therapeutics Inc ( NASDAQ )

Price: $3.34
Change: -0.28 (7.73%)
Volume: 947.5 K
4:00PM ET 5/18/2022
 
 

Enochian Biosciences Inc ( NASDAQ )

Price: $5.91
Change: -0.44 (6.93%)
Volume: 147.3 K
4:00PM ET 5/18/2022
 
 

Mersana Therapeutics Inc ( NASDAQ )

Price: $3.29
Change: -0.08 (2.37%)
Volume: 1.1 M
4:00PM ET 5/18/2022
 
 

Kodiak Sciences Inc ( NASDAQ )

Price: $6.00
Change: -0.11 (1.80%)
Volume: 912.0 K
4:00PM ET 5/18/2022
 
 

22nd Century Group Inc ( NASDAQ )

Price: $1.77
Change: -0.14 (7.33%)
Volume: 1.7 M
4:00PM ET 5/18/2022
 

Read more news Recent News

-- Earnings Flash (MCRB) SERES THERAPEUTICS Posts Q1 Revenue $1.5M
7:02AM ET 5/04/2022 MT Newswires

...

Seres Says Preclinical Data Show SER-155 Reduces Infection, Graft-Versus-Host-Disease
9:15AM ET 3/18/2022 MT Newswires

Seres Therapeutics (MCRB) said Friday that recent preclinical data show SER-155, an investigational microbiome therapeutic, reduces infection and...

--Oppenheimer Adjusts Seres Therapeutics Price Target to $13 From $16, Maintains Outperform Rating
10:46AM ET 3/02/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Seres Therapeutics Q4 Net Loss Narrows as Revenue Increases
7:54AM ET 3/01/2022 MT Newswires

Seres Therapeutics (MCRB) reported a Q4 net loss Tuesday of $0.72 per diluted share, narrowing from a $1.12 loss a year earlier. Analysts polled by...

Company Profile

Business DescriptionSeres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA. View company web site for more details
Address200 Sidney Street
Cambridge, Massachusetts 02139
Phone+1.617.945.9626
Number of Employees145
Recent SEC Filing05/06/2022EFFECT
President, Chief Executive Officer & DirectorEric D. Shaff
Senior Vice President-OperationsMarcus Chapman
EVP, Chief Financial & Accounting OfficerDavid A. Arkowitz
Chief Scientific Officer & Executive VPMatthew R. Henn

Company Highlights

Price Open$3.58
Previous Close$3.34
52 Week Range$3.22 - 25.06
Market Capitalization$308.0 M
Shares Outstanding92.2 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.97
Beta vs. S&P 500N/A
Revenue$28.3 M
Net Profit Margin-61.65%
Return on Equity-70.91%

Analyst Ratings as of 03/02/2022

Buy
7
Overweight
0
Hold
0
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset